BR112022003659A2 - Composições e métodos de tratamento de doenças vasculares - Google Patents

Composições e métodos de tratamento de doenças vasculares

Info

Publication number
BR112022003659A2
BR112022003659A2 BR112022003659A BR112022003659A BR112022003659A2 BR 112022003659 A2 BR112022003659 A2 BR 112022003659A2 BR 112022003659 A BR112022003659 A BR 112022003659A BR 112022003659 A BR112022003659 A BR 112022003659A BR 112022003659 A2 BR112022003659 A2 BR 112022003659A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
vascular diseases
treatment
vpcs
Prior art date
Application number
BR112022003659A
Other languages
English (en)
Inventor
Amrita Singh
Maria Mirotsou
Nutan Prasain
Robert Lanza
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of BR112022003659A2 publication Critical patent/BR112022003659A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições e métodos de tratamento de doenças vasculares. a presente invenção geralmente refere-se a células progenitoras vasculares derivadas do mesoderma (meso-vpcs) e métodos de produção de meso-vpcs. a presente invenção também refere-se a métodos de tratamento de uma doença vascular, tal como isquemia crítica do membro, pela administração de meso-vpcs em um indivíduo.
BR112022003659A 2019-08-28 2020-08-27 Composições e métodos de tratamento de doenças vasculares BR112022003659A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
BR112022003659A2 true BR112022003659A2 (pt) 2022-05-24

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003659A BR112022003659A2 (pt) 2019-08-28 2020-08-27 Composições e métodos de tratamento de doenças vasculares

Country Status (12)

Country Link
US (1) US20220288131A1 (pt)
EP (1) EP4022038A1 (pt)
JP (1) JP2022545737A (pt)
KR (1) KR20220049618A (pt)
CN (1) CN115003794A (pt)
AU (1) AU2020337444A1 (pt)
BR (1) BR112022003659A2 (pt)
CA (1) CA3151636A1 (pt)
IL (1) IL290891A (pt)
MX (1) MX2022002418A (pt)
TW (1) TW202122573A (pt)
WO (1) WO2021041591A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018002038A (es) 2015-08-18 2018-07-06 Astellas Inst For Regenerative Medicine Formulaciones clinicas.
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
US20240132851A1 (en) * 2022-07-19 2024-04-25 Lung Biotechnology Pbc Methods for Differentiating Endothelial Cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
ES2685969T3 (es) 2008-05-06 2018-10-15 Astellas Institute For Regenerative Medicine Células formadoras de colonias hemangioblásticas y células hemangioblásticas no injertables
CA2836843A1 (en) * 2011-06-09 2012-12-13 F. Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into vascular bed cells
WO2013082543A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
MX2018002038A (es) 2015-08-18 2018-07-06 Astellas Inst For Regenerative Medicine Formulaciones clinicas.

Also Published As

Publication number Publication date
KR20220049618A (ko) 2022-04-21
MX2022002418A (es) 2022-03-22
IL290891A (en) 2022-04-01
WO2021041591A1 (en) 2021-03-04
CN115003794A (zh) 2022-09-02
CA3151636A1 (en) 2021-03-04
JP2022545737A (ja) 2022-10-28
US20220288131A1 (en) 2022-09-15
EP4022038A1 (en) 2022-07-06
TW202122573A (zh) 2021-06-16
AU2020337444A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
ECSP18087725A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CL2019000844A1 (es) Compuesto de piridina.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
BR112017017810A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
CL2021000033A1 (es) Nuevos compuestos
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
CR20200649A (es) Agosnistas de tlr7
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
BR112022012126A2 (pt) Compostos antelmínticos compreendendo uma estrutura quinolínica
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.